Morgan Stanley lowered the firm’s price target on Natera (NTRA) to $250 from $265 and keeps an Overweight rating on the shares. The firm updated its model following Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Maintained Buy on Natera: DCF‑Backed Upside and Attractive Long‑Term Growth Profile Despite Lower Price Target
- Natera: Strong Execution, Growing Signatera MRD Franchise, and Multiple Catalysts Support Buy Rating and $260 Target
- Natera: Sustained Outperformance, Conservative 2026 Guidance, and Innovation-Driven Upside Support Buy Rating and $285 Target
- Natera to present new data in geniturinary malignancies at ASCO GU
- Natera price target raised to $260 from $250 at Evercore ISI